Insider transactions

EDGAR

INHIBIKASE THERAPEUTICS, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-16.

Open-market purchases (code P)
1 transactions, 2,068,965 shares
Sum of shares × price per share: 2,999,999.25
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–18 of 18

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-10-19 Filed 2026-10-21Wasserman Scott M. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (310,000) — exercise price 1.645
Acquired (A)310,0000—310,000Direct (D) No
F1
  • F1 The options will vest and become exercisable in equal annual installments over three years commencing from October 19, 2026, subject to the Reporting Person's continued service through each such vesting date.
Open filing 0001193125-26-427830 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-07-31BERMAN DENNIS N Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)21,8541.26
27,536.04

Derived: shares × price per share. Exact value 27536.04.

21,854Direct (D) No— Open filing 0001193125-26-328467 Read from the filing’s XML Dispute this row
2026-07-30 Filed 2026-07-31BERMAN DENNIS N Director
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (21,854) — exercise price 1.26
Disposed (D)21,8540—0Direct (D) No
F1
  • F1 The options are fully vested and exercisable.
Open filing 0001193125-26-328467 Read from the filing’s XML Dispute this row
2026-07-29 Filed 2026-07-31RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Common Stock
Disposed (D)18,030,000——6,970,000Indirect (I) See footnotesNo
F1, F2, F3
  • F1 On July 29, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the Pre-Funded Warrant).
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000815 Read from the filing’s XML Dispute this row
2026-07-29 Filed 2026-07-31RA CAPITAL MANAGEMENT, L.P. 10% ownerRA Capital Healthcare Fund LP 10% ownerKolchinsky Peter 10% ownerShah Rajeev M. 10% owner
J

Other acquisition or disposition (describe transaction)

Derivative security: Pre-Funded Warrant (Right to Buy) — underlying Common Stock (18,030,000) — exercise price 0.001
Acquired (A)18,030,000——18,030,000Indirect (I) See footnotesNo
F1, F4, F2, F3
  • F1 On July 29, 2026, RA Capital Healthcare Fund, L.P. (the Fund) entered into an Exchange Agreement with the Issuer pursuant to which the Fund exchanged, for no additional consideration, 18,030,000 shares of the Issuer's Common Stock for a pre-funded warrant exercisable for up to 18,030,000 shares of the Issuer's Common Stock at an exercise price of $0.001 per share (the Pre-Funded Warrant).
  • F4 The Pre-Funded Warrant has no expiration date and is exercisable immediately. Notwithstanding the foregoing, the Fund shall not be entitled to exercise the Pre-Funded Warrant to the extent that it would cause the aggregate number of shares of Common Stock beneficially owned by the Fund, together with its Attribution Parties (as defined in the Pre-Funded Warrant), to exceed 9.99% of the total number of issued and outstanding shares of Common Stock of the Issuer following such exercise.
  • F2 RA Capital Management, L.P. (the Adviser) is the investment manager for the Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the Adviser GP), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  • F3 Held directly by the Fund.
Open filing 0001231919-26-000815 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Canner David Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290476 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30BERMAN DENNIS N Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290477 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Bellini Roberto Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290474 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Kush Arvind Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290475 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Aurentz Vincent Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290472 Read from the filing’s XML Dispute this row
2026-06-26 Filed 2026-06-30Munshi Amit Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (155,000) — exercise price 1.91
Acquired (A)155,0000—155,000Direct (D) No
F1
  • F1 The options will vest on the earlier of June 26, 2027 or the day prior to the next annual meeting of stockholders, subject to the director's continued service through such date.
Open filing 0001193125-26-290470 Read from the filing’s XML Dispute this row
2026-02-21 Filed 2026-02-24Cabell Christopher Officer: President Head of RD
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)338,2820—676,564Direct (D) No
F1
  • F1 As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 338,282 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 338,282 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.
Open filing 0001193125-26-068077 Read from the filing’s XML Dispute this row
2026-02-21 Filed 2026-02-24Munshi Amit Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)19,0890—38,176Direct (D) No
F1
  • F1 As previously reported on a Form 4 filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 19,089 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 19,089 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.
Open filing 0001193125-26-068063 Read from the filing’s XML Dispute this row
2026-02-21 Filed 2026-02-24Aurentz Vincent Director
D

Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Common Stock
Disposed (D)255,2990—510,596Direct (D) No
F1
  • F1 As previously reported on a Form 3/A filed on August 28, 2025, the Reporting Person received shares of Issuer common stock as merger consideration upon the completion of the acquisition of CorHepta Pharmaceuticals, Inc. on February 21, 2025 (the Closing Date), with 255,299 shares subject to forfeiture if a certain milestone is not achieved by the first anniversary of the Closing Date. On February 21, 2026, it was determined that such milestone was not achieved, resulting in the forfeiture of all 255,299 shares. The Reporting Person received no consideration from the Issuer in connection with such forfeiture.
Open filing 0001193125-26-068079 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Cabell Christopher Officer: President Head of RD
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (900,117) — exercise price 2.01
Acquired (A)900,1170—900,117Direct (D) No
F1
  • F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.
Open filing 0001193125-26-006350 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07McIntyre David Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (986,319) — exercise price 2.01
Acquired (A)986,3190—986,319Direct (D) No
F1
  • F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.
Open filing 0001193125-26-006343 Read from the filing’s XML Dispute this row
2026-01-05 Filed 2026-01-07Iwicki Mark T Director · Officer: Chief Executive Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (Right to Buy) — underlying Common Stock (4,982,706) — exercise price 2.01
Acquired (A)4,982,7060—4,982,706Direct (D) No
F1
  • F1 The shares underlying the option shall vest and become exercisable in 36 equal monthly installments commencing from January 5, 2026, subject to the Reporting Person's continued employment through each such vesting date.
Open filing 0001193125-26-006351 Read from the filing’s XML Dispute this row
2025-11-21 Filed 2025-11-24Sands Capital Life Sciences Pulse Fund II, L.P. 10% ownerSands Capital Alternatives, LLC 10% ownerSANDS FRANK M. 10% owner
P

Open market or private purchase of non-derivative or derivative security

Common Stock
Acquired (A)2,068,9651.45
2,999,999.25

Derived: shares × price per share. Exact value 2999999.25.

13,018,965Direct (D) No
F5, F1, F2, F3, F4
  • F5 The securities reported herein were acquired in an underwritten public offering by the Issuer at the public offering price of $1.45 per share.
  • F1 This report does not include a Series A-1 warrant to purchase 5,475,000 shares of Common Stock (the Series A-1 Warrant) or a Series B-1 warrant to purchase 10,068,120 shares of Common Stock (the Series B-1 Warrant), in each case held by Sands Capital Life Sciences Pulse Fund II, L.P. (Sands Pulse Fund II), each of which was purchased by Sands Pulse Fund II from the Issuer pursuant to that certain securities purchase agreement dated October 9, 2024 between the Issuer and, among certain other institutional and accredited investors, Sands Pulse Fund II (the Purchase Agreement).
  • F2 (Continued from footnote 1) The Series A-1 Warrant is exercisable on the earlier of (a) the 75th calendar day following the initial filing date of the registration statement covering the resale of the shares of Common Stock underlying the Series A-1 warrants and Series B-1 warrants issued pursuant to the Purchase Agreement (the Warrant Initial Registration Statement) if the Securities and Exchange Commission (SEC) notifies the Issuer that it will review the Warrant Initial Registration Statement and (b) the fifth business day after the date the Issuer is notified (orally or in writing, whichever is earlier) by the SEC that the Warrant Initial Registration Statement will not be reviewed or(even if previously subject to review pursuant to clause (a) of this sentence) will not be subject to further review (the Initial Exercise Date). The Series B-1 Warrant is exercisable on the Initial Exercise Date, provided that, to the extent exercisable,
  • F3 (Continued from footnote 2) the Series A-1 Warrant issued to Sands Pulse Fund II has been exercised in full either by Sands Pulse Fund II or its transferee permitted by the terms of the Series A-1 Warrant. The Series A-1 Warrant and the Series B-1 Warrant each provide that the holder of such warrant will not have the right to exercise any portion of such warrant if such holder, together with its affiliates, would beneficially own in excess of 19.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. The Reporting Persons each disclaim beneficial ownership of the shares of Common Stock underlying each of the Series A-1 Warrant and Series B-1Warrant because neither the Series A-1 Warrant nor the Series B-1 Warrant is exercisable within 60 days of this filing and such date is not determinable at this time.
  • F4 Represents shares of common stock, par value $0.001, of the Issuer (Common Stock) held by Sands Pulse Fund II. Sands Capital Alternatives, LLC (Sands Alternatives) is the investment manager of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, L.P. (Sands Pulse GP L.P.) is the general partner of Sands Pulse Fund II. Sands Capital Life Sciences Pulse Fund II-GP, LLC (Sands Pulse GP LLC) is the general partner of Sands Pulse GP L.P. Sands Alternatives, Sands Pulse GP L.P. and Sands Pulse GPLLC each disclaim beneficial ownership of such securities except to the extent of their relative pecuniary interest therein. Frank M. Sands holds ultimate voting and investment power over these securities and may be deemed to beneficially own the securities. Mr. Sands disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
Open filing 0001875620-25-000025 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 7,211 filings read, the latest filed 2026-11-13. Prior quarter ending 2026-06-30: 9,150 filings read.

Showing 1–50 of 69

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
Sands Capital Alternatives, LLC 13,018,965 SH26,819,068 dollarsUnchanged Prior quarter: 13,018,965Open filing 0001846444-26-000013 Filed 2026-11-13 Dispute this row
BlackRock, Inc. Partly reported under another manager8,564,431 SH17,599,906 dollarsHigher by 796,374 Prior quarter: 7,768,057Open filing 0002012383-26-003985 Filed 2026-11-13 Dispute this row
Siren, L.L.C. Partly reported under another manager5,850,000 SH12,021,750 dollarsUnchanged Prior quarter: 5,850,000Open filing 0002005245-26-000013 Filed 2026-11-12 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 5,053,455 SH10,384,850 dollarsHigher by 118,101 Prior quarter: 4,935,354Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
Kalehua Capital Management LLC 3,821,890 SH7,853,984 dollarsLower by 3,821,890 Prior quarter: 7,643,780Open filing 0002106181-26-000010 Filed 2026-11-13 Dispute this row
Spruce Street Capital LP 3,581,603 SH7,360,194 dollarsUnchanged Prior quarter: 3,581,603Open filing 0002050194-26-000006 Filed 2026-11-13 Dispute this row
GEODE CAPITAL MANAGEMENT, LLC Partly reported under another manager3,063,159 SH6,295,955 dollarsHigher by 456,030 Prior quarter: 2,607,129Open filing 0001214717-26-000012 Filed 2026-11-06 Dispute this row
STATE STREET CORP Partly reported under another manager2,222,640 SH4,567,525 dollarsHigher by 313,539 Prior quarter: 1,909,101Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
Nantahala Capital Management, LLC 1,951,863 SH4,011,078 dollarsLower by 3,451,863 Prior quarter: 5,403,726Open filing 0001104659-26-127125 Filed 2026-11-13 Dispute this row
Tyro Capital Management LLC 1,368,756 SH2,812,793 dollarsNot in the prior quarter’s filings read Open filing 0001915395-26-000018 Filed 2026-11-12 Dispute this row
VANGUARD PORTFOLIO MANAGEMENT LLC 984,371 SH2,022,882 dollarsHigher by 174,881 Prior quarter: 809,490Open filing 0002100121-26-001150 Filed 2026-11-13 Dispute this row
Kennondale Capital Management LLC 721,961 SH1,483,630 dollarsHigher by 155,978 Prior quarter: 565,983Open filing 0001754960-26-000990 Filed 2026-11-09 Dispute this row
VANGUARD FIDUCIARY TRUST CO 681,099 SH1,399,658 dollarsHigher by 73,839 Prior quarter: 607,260Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Stonepine Capital Management, LLC 647,285 SH1,330,171 dollarsHigher by 251,106 Prior quarter: 396,179Open filing 0001440771-26-000027 Filed 2026-11-13 Dispute this row
UBS Group AG Partly reported under another manager621,566 SH1,277,318 dollarsHigher by 416,912 Prior quarter: 204,654Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
Pathstone Holdings, LLC 510,603 SH1,049,289 dollarsHigher by 7 Prior quarter: 510,596Open filing 0002011612-26-000005 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager417,043 SH857,023 dollarsLower by 8,449 Prior quarter: 425,492Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
Bank of New York Mellon Corp Partly reported under another manager333,914 SH686,193 dollarsHigher by 30,788 Prior quarter: 303,126Open filing 0001390777-26-000121 Filed 2026-11-05 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager321,036 SH648,493 dollarsHigher by 4,462 Prior quarter: 316,574Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
MORGAN STANLEY Partly reported under another manager293,732 SH603,619 dollarsHigher by 179,726 Prior quarter: 114,006Open filing 0000895421-26-000309 Filed 2026-11-13 Dispute this row
JONES FINANCIAL COMPANIES LLLP Partly reported under another manager190,538 SH392,508 dollarsHigher by 62,047 Prior quarter: 128,491Open filing 0001193125-26-459442 Filed 2026-11-13 Dispute this row
ALPS ADVISORS INC 183,550 SH377,195 dollarsHigher by 49,548 Prior quarter: 134,002Open filing 0001398344-26-019318 Filed 2026-11-03 Dispute this row
BLAIR WILLIAM CO/IL 155,953 SH320,483 dollarsLower by 127 Prior quarter: 156,080Open filing 0001104659-26-124894 Filed 2026-11-10 Dispute this row
AMERICAN CENTURY COMPANIES INC Partly reported under another manager128,829 SH264,744 dollarsHigher by 79,831 Prior quarter: 48,998Open filing 0000748054-26-000008 Filed 2026-11-12 Dispute this row
RHUMBLINE ADVISERS 120,087 SH246,770 dollarsHigher by 73 Prior quarter: 120,014Open filing 0001115418-26-000015 Filed 2026-11-10 Dispute this row
FMR LLC Partly reported under another manager111,048 SH228,202 dollarsHigher by 7,321 Prior quarter: 103,727Open filing 0000315066-26-002964 Filed 2026-11-10 Dispute this row
DEUTSCHE BANK AG\ Partly reported under another manager110,779 SH228,205 dollarsLower by 15,898 Prior quarter: 126,677Open filing 0000948046-26-000083 Filed 2026-11-06 Dispute this row
DIMENSIONAL FUND ADVISORS LP Partly reported under another manager103,073 SH211,461 dollarsNot in the prior quarter’s filings read Open filing 0000354204-26-001096 Filed 2026-11-04 Dispute this row
BARCLAYS PLC Partly reported under another manager67,839 SH139,410 dollarsHigher by 48,114 Prior quarter: 19,725Open filing 0000312069-26-000241 Filed 2026-11-06 Dispute this row
Invesco Ltd. Partly reported under another manager58,526 SH120,271 dollarsLower by 3,577 Prior quarter: 62,103Open filing 0000914208-26-000462 Filed 2026-11-12 Dispute this row
Arax Advisory Partners Partly reported under another manager54,421 SH111,835 dollarsHigher by 47,300 Prior quarter: 7,121Open filing 0001586767-26-000009 Filed 2026-11-12 Dispute this row
Russell Investments Group, Ltd. Partly reported under another manager54,077 SH111,128 dollarsHigher by 452 Prior quarter: 53,625Open filing 0001193125-26-451241 Filed 2026-11-06 Dispute this row
Abel Hall, LLC Partly reported under another manager53,311 SH109,554 dollarsHigher by 6,959 Prior quarter: 46,352Open filing 0002013339-26-000005 Filed 2026-10-19 Dispute this row
Spark Investment Management LLC 52,100 SH107,066 dollarsHigher by 36,600 Prior quarter: 15,500Open filing 0000899140-26-001312 Filed 2026-11-13 Dispute this row
SEI INVESTMENTS CO Partly reported under another manager47,962 SH98,562 dollarsUnchanged Prior quarter: 47,962Open filing 0000350894-26-000059 Filed 2026-11-10 Dispute this row
BNP PARIBAS FINANCIAL MARKETS Partly reported under another manager40,477 SH83,180 dollarsHigher by 19,899 Prior quarter: 20,578Open filing 0001166588-26-000012 Filed 2026-11-12 Dispute this row
Sanctuary Advisors, LLC 40,287 SH82,790 dollarsHigher by 17,486 Prior quarter: 22,801Open filing 0001777271-26-000009 Filed 2026-11-13 Dispute this row
Police Firemen's Retirement System of New Jersey Partly reported under another manager40,099 SH82,403 dollarsLower by 1,495 Prior quarter: 41,594Open filing 0002040686-26-000007 Filed 2026-11-09 Dispute this row
Vanguard Global Advisers, LLC 37,180 SH76,405 dollarsHigher by 634 Prior quarter: 36,546Open filing 0001811242-26-000017 Filed 2026-11-13 Dispute this row
CITIGROUP INC Partly reported under another manager32,955 SH67,722 dollarsLower by 23,135 Prior quarter: 56,090Open filing 0000831001-26-000052 Filed 2026-11-04 Dispute this row
IEQ CAPITAL, LLC 32,159 SH66,087 dollarsLower by 36,352 Prior quarter: 68,511Open filing 0001779789-26-000005 Filed 2026-11-10 Dispute this row
VOYA INVESTMENT MANAGEMENT LLC Partly reported under another manager27,697 SH56,917 dollarsHigher by 2,411 Prior quarter: 25,286Open filing 0001068837-26-000006 Filed 2026-11-10 Dispute this row
Cerity Partners LLC 27,465 SH56,442 dollarsLower by 10,549 Prior quarter: 38,014Open filing 0001172661-26-005020 Filed 2026-11-13 Dispute this row
MANUFACTURERS LIFE INSURANCE COMPANY, THE Partly reported under another manager27,054 SH55,596 dollarsUnchanged Prior quarter: 27,054Open filing 0001145443-26-000111 Filed 2026-11-13 Dispute this row
ProShare Advisors LLC 18,130 SH37,258 dollarsHigher by 2,235 Prior quarter: 15,895Open filing 0001357955-26-000005 Filed 2026-10-29 Dispute this row
Centiva Capital, LP 17,553 SH36,071 dollarsNot in the prior quarter’s filings read Open filing 0001172661-26-005016 Filed 2026-11-13 Dispute this row
Mariner, LLC 15,466 SH31,774 dollarsLower by 7,673 Prior quarter: 23,139Open filing 0001580642-26-007648 Filed 2026-11-12 Dispute this row
CIBC Bancorp USA Inc. Partly reported under another manager14,275 SH29,335 dollarsNot in the prior quarter’s filings read Open filing 0001298088-26-000029 Filed 2026-11-13 Dispute this row
XPONANCE LLC 12,845 SH26,396 dollarsHigher by 1,295 Prior quarter: 11,550Open filing 0001172661-26-004817 Filed 2026-11-03 Dispute this row
VICTORY CAPITAL MANAGEMENT INC 12,178 SH25,026 dollarsHigher by 674 Prior quarter: 11,504Open filing 0001040188-26-000051 Filed 2026-11-10 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Soleus Capital Management, L.P. 10,875,000 SH
  • Trails Edge Capital Partners, LP 9,051,318 SH
  • Fairmount Funds Management LLC 8,625,000 SH
  • ADAR1 Capital Management, LLC 7,387,205 SH
  • Blackstone Inc. 5,938,276 SH
  • Commodore Capital LP 5,397,488 SH
  • MILLENNIUM MANAGEMENT LLC 4,028,102 SH
  • Saturn V Capital Management LP 3,869,056 SH
  • Squadron Capital Management LLC 3,000,000 SH
  • SummitTX Capital, L.P. 1,780,262 SH
  • Integral Health Asset Management, LLC 1,350,000 SH
  • NORTHERN TRUST CORP 878,585 SH
  • TWO SIGMA INVESTMENTS, LP 806,264 SH
  • SPHERA FUNDS MANAGEMENT LTD. 649,309 SH
  • AQR CAPITAL MANAGEMENT LLC 468,197 SH
  • Seven Fleet Capital Management LP 346,900 SH
  • CHARLES SCHWAB INVESTMENT MANAGEMENT INC 275,041 SH
  • Sixth Street Partners Management Company, L.P. 275,041 SH
  • Rangeley Capital, LLC 220,000 SH
  • BANK OF AMERICA CORP /DE/ 108,024 SH
  • WELLS FARGO COMPANY/MN 101,841 SH
  • PRICE T ROWE ASSOCIATES INC /MD/ 99,632 SH
  • CITADEL ADVISORS LLC 74,349 SH
  • MetLife Investment Management, LLC 62,524 SH
  • MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. 55,905 SH
  • GOLDMAN SACHS GROUP INC 50,170 SH
  • Quadrature Capital Ltd 48,413 SH
  • NEW YORK STATE COMMON RETIREMENT FUND 47,900 SH
  • TRANSCEND CAPITAL ADVISORS, LLC 45,298 SH
  • XTX Topco Ltd 34,339 SH
  • INTECH INVESTMENT MANAGEMENT LLC 28,626 SH
  • CAXTON CORP 28,453 SH
  • Lynx1 Capital Management LP 20,000 SH
  • WEALTH ENHANCEMENT ADVISORY SERVICES, LLC 18,759 SH
  • PRUDENTIAL FINANCIAL INC 18,290 SH
  • MERCER GLOBAL ADVISORS INC /ADV 16,781 SH
  • SUSQUEHANNA INTERNATIONAL GROUP, LLP 16,242 SH
  • ALLIANCEBERNSTEIN L.P. 15,320 SH
  • Tower Research Capital LLC (TRC) 15,204 SH
  • Squarepoint Ops LLC 12,854 SH
  • ROYAL BANK OF CANADA 12,199 SH
  • Legal General Group Plc 12,078 SH
  • Integrated Wealth Concepts LLC 1,256 SH
  • Quarry LP 55 SH
  • Clearstead Advisors, LLC 6 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
RA Capital Management, L.P. Common Stock, $0.001 par value per share9.914,653,994.0007/29/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000206 Dispute this row
Peter Kolchinsky Common Stock, $0.001 par value per share9.914,653,994.0007/29/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000206 Dispute this row
Rajeev Shah Common Stock, $0.001 par value per share9.914,653,994.0007/29/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000206 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share9.914,653,994.0007/29/2026 Filed 2026-07-31SCHEDULE 13G/AAmendment 1Open filing 0001346824-26-000206 Dispute this row
RA Capital Management, L.P. Common Stock, $0.001 par value per share15.925,000,000.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001346824-26-000193 Dispute this row
Peter Kolchinsky Common Stock, $0.001 par value per share15.925,000,000.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001346824-26-000193 Dispute this row
Rajeev Shah Common Stock, $0.001 par value per share15.925,000,000.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001346824-26-000193 Dispute this row
RA Capital Healthcare Fund, L.P. Common Stock, $0.001 par value per share15.925,000,000.0007/10/2026 Filed 2026-07-17SCHEDULE 13GOpen filing 0001346824-26-000193 Dispute this row
Perceptive Advisors LLC Common Stock, $0.001 par value6.910,320,87506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-352638 Dispute this row
Joseph Edelman Common Stock, $0.001 par value6.910,320,87506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-352638 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.001 par value6.910,320,87506/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 3Open filing 0001193125-26-352638 Dispute this row
Nantahala Capital Management, LLC Common Stock, $0.001 par value4.305,810,487.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097282 Dispute this row
Wilmot B. Harkey Common Stock, $0.001 par value4.305,810,487.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097282 Dispute this row
Daniel Mack Common Stock, $0.001 par value4.305,810,487.0006/30/2026 Filed 2026-08-14SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-097282 Dispute this row
Sands Capital Life Sciences Pulse Fund II, L.P. Common Stock, $0.001 par value per share9.313,018,965.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 3Open filing 0001875620-26-000017 Dispute this row
Sands Capital Alternatives, LLC Common Stock, $0.001 par value per share9.313,018,965.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 3Open filing 0001875620-26-000017 Dispute this row
SANDS FRANK M. Common Stock, $0.001 par value per share9.313,018,965.0006/30/2026 Filed 2026-08-13SCHEDULE 13G/AAmendment 3Open filing 0001875620-26-000017 Dispute this row
BlackRock, Inc. Common Stock5.97,768,00406/30/2026 Filed 2026-07-28SCHEDULE 13GOpen filing 0002012383-26-002526 Dispute this row
Perceptive Advisors LLC Common Stock, $0.001 par value8.912,635,87503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-226561 Dispute this row
Joseph Edelman Common Stock, $0.001 par value8.912,635,87503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-226561 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.001 par value8.912,635,87503/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 2Open filing 0001193125-26-226561 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.001 par value9.913,860,028.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-062874 Dispute this row
ADAR1 Capital Management GP, LLC Common Stock, $0.001 par value8.511,832,998.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-062874 Dispute this row
Daniel Schneeberger Common Stock, $0.001 par value9.913,860,028.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 3Open filing 0001104659-26-062874 Dispute this row
Commodore Capital LP Common Stock, $0.001 par value9.914,054,940.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000019 Dispute this row
Commodore Capital Master LP Common Stock, $0.001 par value9.914,054,940.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000019 Dispute this row
Robert Egen Atkinson Common Stock, $0.001 par value9.914,054,940.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000019 Dispute this row
Michael Kramarz Common Stock, $0.001 par value9.914,054,940.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001831942-26-000019 Dispute this row
Trails Edge Capital Partners, LP Common Stock, $0.001 par value6.18,057,345.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-023791 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Stock, $0.001 par value6.18,057,345.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-023791 Dispute this row
Ortav Yehudai Common Stock, $0.001 par value6.18,057,345.0003/31/2026 Filed 2026-05-15SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-023791 Dispute this row
Fairmount Funds Management LLC Common Stock, par value $0.001 per share9.912,461,101.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016478 Dispute this row
Fairmount Healthcare Fund II L.P. Common Stock, par value $0.001 per share9.912,461,101.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016478 Dispute this row
Peter Harwin Common Stock, par value $0.001 per share9.912,461,101.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016478 Dispute this row
Tomas Kiselak Common Stock, par value $0.001 per share9.912,461,101.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016478 Dispute this row
ADAR1 Capital Management, LLC Common Stock, $0.001 par value9.912,523,371.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016623 Dispute this row
ADAR1 Capital Management GP, LLC Common Stock, $0.001 par value9.912,692,387.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016623 Dispute this row
Daniel Schneeberger Common Stock, $0.001 par value9.912,523,371.0012/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 2Open filing 0001104659-26-016623 Dispute this row
Perceptive Advisors LLC Common Stock, $0.001 par value9.9912,816,64312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-054524 Dispute this row
Joseph Edelman Common Stock, $0.001 par value9.9912,816,64312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-054524 Dispute this row
Perceptive Life Sciences Master Fund, Ltd. Common Stock, $0.001 par value9.9912,816,64312/31/2025 Filed 2026-02-17SCHEDULE 13G/AAmendment 1Open filing 0001193125-26-054524 Dispute this row
Sands Capital Life Sciences Pulse Fund II, L.P. Common Stock, $0.001 par value per share10.813,018,965.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001875620-26-000002 Dispute this row
Sands Capital Alternatives, LLC Common Stock, $0.001 par value per share10.813,018,965.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001875620-26-000002 Dispute this row
SANDS FRANK M. Common Stock, $0.001 par value per share10.813,018,965.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 2Open filing 0001875620-26-000002 Dispute this row
Nantahala Capital Management, LLC Common Stock, $0.001 par value5.687,037,916.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015334 Dispute this row
Wilmot B. Harkey Common Stock, $0.001 par value5.687,037,916.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015334 Dispute this row
Daniel Mack Common Stock, $0.001 par value5.687,037,916.0012/31/2025 Filed 2026-02-13SCHEDULE 13G/AAmendment 1Open filing 0001104659-26-015334 Dispute this row
Trails Edge Capital Partners, LP Common Stock, $0.001 par value5.16,145,198.0012/23/2025 Filed 2025-12-31SCHEDULE 13GOpen filing 0001493152-25-029834 Dispute this row
Trails Edge Biotechnology Master Fund, LP Common Stock, $0.001 par value5.16,145,198.0012/23/2025 Filed 2025-12-31SCHEDULE 13GOpen filing 0001493152-25-029834 Dispute this row
Ortav Yehudai Common Stock, $0.001 par value5.16,145,198.0012/23/2025 Filed 2025-12-31SCHEDULE 13GOpen filing 0001493152-25-029834 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,092,408 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
20151
2016204,322
2017202,494
2018202,048
2019193,638
2020144,184
2021224,474
202240,015
2023199,811
2024185,386
2025235,520
2026254,737

Filings made before the SEC required XML are listed, not extracted.

Back to INHIBIKASE THERAPEUTICS, INC.